BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, April 25, 2026
Home » Blogs » BioWorld Perspectives » Drug quality from a patient’s perspective

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Oncology

Drug quality from a patient’s perspective

Sep. 10, 2017
By Mari Serebrov

Mari's blog pic recallDirt. Excrement. Glass. Hair. Insects. Mold. Rodent infestation. Scouring pad fibers. Unknown particulates. They’re words too often mentioned in FDA warning letters that describe manufacturing conditions for supposedly sterile drugs.

A few years ago when I was a cancer patient hooked up to an I.V. drip for three to four hours every two weeks, I found reading those warning letters a horrifying experience. With a cocktail of generic and brand drugs coming from who knows where being pumped into the port resting a few inches from my heart, I cringed at the thought of what might be entering my vein. Especially when a company excused the scouring pad fibers and insect pieces as being “within the acceptable range.”

Yes, I knew the FDA inspected manufacturing facilities, but it gave me little comfort. Those inspections could be few and far between, given the agency’s limited resources and its expanding responsibilities across the world. According to the Government Accountability Office, one-third of foreign manufacturing plants and 14 percent of the plants in the U.S. had never been inspected. And it can take the FDA months or even years to become aware of and respond to unsanitary manufacturing conditions. Thus, I wasn’t 100 percent confident about the quality of the saline, steroids and chemo drugs dripping into my port.

Before chemo began, I did my research. I read the oncologist’s printouts on every drug he planned to use. I found more information online. I asked my oncologist questions and sought out second opinions from nationally recognized cancer experts on potential side effects and contraindications.

But there was one thing I couldn’t do – protect myself from a contaminated drug. There was nothing to tell me who had made the API or which manufacturing plants had produced the finished drugs I was being given. I had no idea if those plants had been inspected within the past decade, if they had addressed shortcomings the inspectors pointed out or if they had outstanding warning letters citing serious quality problems. And if the FDA issued a safety alert involving a specific manufacturer and batch or lot numbers, I wouldn’t know whether it should be a cause for alarm.

I could only trust.

Trust that someone in my doctor’s office had been informed of the alert and diligently checked the inventory, before I arrived for my infusion or shot. Trust that the FDA had done a recent inspection at the facilities making my drugs. Trust that it had already acted on any issues it found. (As BioWorld has reported, it can be up to a year before the FDA takes action against manufacturing plants with serious problems.) Trust that the drug companies took those issues seriously and were forthcoming with problems that had come up since their last inspection. Trust that the employees at the manufacturing plants knew, and cared, that my life was literally in their hands.

Ironically, while I was on chemo, the FDA put out a notice about a recall of certain organic frozen meals containing spinach that may have been contaminated with Listeria monocytogenes, an organism that can be fatal for people with weakened immune systems. In other words, people like me.

Because I had the brand, the name of the manufacturer, bar codes, lot numbers and expiration dates, I knew the recall could affect me. I had two of those meals in my freezer. In fact, I had been planning to have one of them for dinner that night. Instead, my husband returned the dinners to the store, which had just posted signs about the recall in its frozen foods section for everybody to see.

Were it so with drugs. . . .

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 24, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 21, 2026
  • Boy cupping ear with soundwave graphic

    A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

    BioWorld
    Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
  • Green arrow on blue abstract background

    Psychedelic space expanding on Trump’s EO

    BioWorld
    Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
  • Illustration of metastatic cancer

    At AACR: Epigenetic fingerprints in metastases track tumor origin

    BioWorld
    When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing